Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the BariClot tool using the MBSAQIP database
Bariatric surgery is an effective treatment for severe obesity; however, postoperative venous thromboembolism (VTE) remains a leading cause of morbidity and mortality. The objective of this study is to develop a tool to stratify individuals undergoing laparoscopic bariatric surgery according to their 30-day VTE risk.
This is a retrospective cohort study of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database. This registry collects data specific for metabolic or bariatric surgery with 30-day outcomes from 791 centers. Individuals undergoing primary laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) were included. Characteristics associated with 30-day VTE were identified using univariate and multivariable analyses. A predictive model, BariClot, was derived from a randomly-generated derivation cohort using a forward selection algorithm. BariClot’s robustness was tested against a validation cohort of subjects not included in the derivation cohort. The calibration and discrimination of two previously published VTE risk tools were assessed in the MBSAQIP population and compared to BariClot.
A total of 274,221 patients underwent LRYGB or LSG. Overall, 1106 (0.4%) patients developed VTE, 452 (0.2%) developed pulmonary embolism, and 43 (0.02%) died due to VTE. VTE was the most commonly identified cause of 30-day mortality. A prediction model to assess for risk of VTE, BariClot, was derived and validated. BariClot consists of history of VTE, operative time, race, and functional status. It stratifies individuals into very high (> 2%), high (1–2%), medium (0.3–1%), and low risk groups (< 0.3%). This model accurately predicted events in the validation cohort and outperformed previously published scoring systems.
BariClot is a predictive tool that stratifies individuals undergoing bariatric surgery based on 30-day VTE risk. Stratifying low- and high-risk populations for VTE allows for informed clinical decision-making and potentially enables further research on customized prophylactic measures for low- and high-risk populations.
KeywordsBariatric surgery Venous thromboembolism Deep vein thrombosis Pulmonary embolism Sleeve gastrectomy Roux-en-Y gastric bypass
Compliance with ethical standards
Drs. Jerry T. Dang, Noah Switzer, Megan Delisle, Michael Laffin, Richdeep Gill, Daniel W. Birch, and Shahzeer Karmali have no conflict of interest or financial ties to disclose.
- 9.Hamad GG, Choban PS (2005) Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 15:1368–1374. https://doi.org/10.1381/096089205774859245 CrossRefPubMedGoogle Scholar
- 13.Raftopoulos I, Martindale C, Cronin A, Steinberg J (2008) The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc 22:2384–2391. https://doi.org/10.1007/s00464-008-0031-9 CrossRefPubMedGoogle Scholar
- 16.American Society for Metabolic T, Surgery Clinical Issues Committee B (2013) ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients The American Society for Metabolic and Bariatric Surgery Clinical Issues Committee*. Surg Obes Relat Dis 9:493–497. https://doi.org/10.1016/j.soard.2013.03.006 CrossRefGoogle Scholar
- 20.2016 MBSAQIP Standards Manual. https://www.facs.org/quality-programs/mbsaqip/standards. Accessed 24 Jul 2017
- 21.StataCorp (2015) Stata statistical software: release 14. StataCorp LP, College Station, TXGoogle Scholar
- 23.Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (2017) MBSAQIP PUF variables and definitions. https://www.facs.org/quality-programs/mbsaqip/participant-use. Accessed 22 Dec 2017
- 24.Virchow R (1862) Gesammelte abhandlungen zur wissenschaftlichen medicin von Rudolf Virchow. G. Grotesche BuchhandlungGoogle Scholar
- 28.White RH, Zhou H, Romano PS (1998) Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 128:737–740. https://doi.org/10.7326/0003-4819-128-9-199805010-00006 CrossRefPubMedGoogle Scholar
- 30.Heit JA, Beckman MG, Bockenstedt PL, Grant AM, Key NS, Kulkarni R, Manco-Johnson MJ, Moll S, Ortel TL, Philipp CS (2010) Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol 85:467–471. https://doi.org/10.1002/ajh.21735 CrossRefPubMedGoogle Scholar
- 32.Clements RH, Yellumahanthi K, Ballem N, Wesley M, Bland KI (2009) Pharmacologic prophylaxis against venous thromboembolic complications is not mandatory for all laparoscopic Roux-en-Y gastric bypass procedures. J Am Coll Surg 208:917–921. https://doi.org/10.1016/J.JAMCOLLSURG.2009.01.034 CrossRefPubMedGoogle Scholar
- 34.Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC, Guske PJ, Kane JM, Gordon N, Sambol NC (2008) Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 4:625–631. https://doi.org/10.1016/J.SOARD.2007.11.010 CrossRefPubMedGoogle Scholar
- 37.Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut ER, Sharma R, Shermock K, Chelladurai Y, Singh S, Segal JB (2013) Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery. JAMA Surg 148:675. https://doi.org/10.1001/jamasurg.2013.72 CrossRefPubMedGoogle Scholar
- 39.Singh K, Podolsky ER, Um S, Saba S, Saeed I, Aggarwal L, Zaya M, Castellanos A (2012) Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 22:47–51. https://doi.org/10.1007/s11695-011-0397-y CrossRefPubMedGoogle Scholar
- 40.Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM (2012) Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e227S–e277S. https://doi.org/10.1378/CHEST.11-2297 CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY, Cohen ME (2013) Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg 217:833–842.e3. https://doi.org/10.1016/J.JAMCOLLSURG.2013.07.385 CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Liu Y, Cohen ME, Ko CY, Bilimoria KY, Hall BL (2016) Considerations in releasing equations for the American College of Surgeons NSQIP surgical risk calculator: in reply to Wanderer and Ehrenfeld. J Am Coll Surg 223:674–675. https://doi.org/10.1016/J.JAMCOLLSURG.2016.06.009 CrossRefPubMedGoogle Scholar
- 44.Winegar DA, Sherif B, Pate V, DeMaria EJ (2011) Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of excellence participants: analysis of the Bariatric outcomes longitudinal database. Surg Obes Relat Dis 7:181–188. https://doi.org/10.1016/J.SOARD.2010.12.008 CrossRefPubMedGoogle Scholar